Matinas Biopharma shares are trading higher after the company announced complete clinical resolution of a patient's recurrent hemorrhagic cystitis due to Candida krusei following treatment with the company's MAT2203.
Portfolio Pulse from Benzinga Newsdesk
Matinas Biopharma announced complete clinical resolution of a patient's recurrent hemorrhagic cystitis due to Candida krusei following treatment with the company's MAT2203. This news has led to a rise in the company's share prices.
October 11, 2023 | 5:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Matinas Biopharma's shares are trading higher after successful treatment with the company's MAT2203. This indicates a positive impact on the company's stock.
The successful treatment with MAT2203 has led to a rise in Matinas Biopharma's share prices. This indicates a positive sentiment among investors, which could lead to a further increase in the company's stock prices in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100